Analysts expect Boston Scientific to report consensus revenue of $5.38 billion (+6.5% YoY) and adjusted EPS of $0.83 (+10.7% YoY), while the stock trades near $44.25 against an average price target of $72.43. Investors are primarily focused on the performance of the WATCHMAN franchise following management's warning of a slowdown in standalone procedures. The company recently slashed its full-year outlook as it navigates competitive erosion in its electrophysiology segment and a shift toward concomitant procedures for heart implants. Despite these headwinds, analysts remain constructive on the long-term potential of the FARAPULSE pulsed field ablation system and the pending multi-billion dollar acquisition of Penumbra.